These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Comparative survival analysis of adjuvant therapy with iodine-131-labeled lipiodol to hepatic resection of primary hepatocellular carcinoma: a meta-analysis. Gong L; Shi L; Sun J; Yuan WS; Chen JF; Liu P; Gong F; Dong JH Nucl Med Commun; 2014 May; 35(5):484-92. PubMed ID: 24492679 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and application of 188Re-MN-16ET/Lipiodol in a hepatocellular carcinoma animal model. Tang IC; Luo TY; Liu SW; Chan SH; Kung HC; Peng CL; Lin WY; Chang Y; Lin WJ Nucl Med Biol; 2011 Oct; 38(7):1043-52. PubMed ID: 21831647 [TBL] [Abstract][Full Text] [Related]
15. On developing a pragmatic strategy for clinical trials: A case study of hepatocellular carcinoma. Gandhi M; Tan SB; Chung Yaw Fui A; Machin D Contemp Clin Trials; 2015 Jul; 43():252-9. PubMed ID: 26111924 [TBL] [Abstract][Full Text] [Related]
16. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Raoul JL; Guyader D; Bretagne JF; Heautot JF; Duvauferrier R; Bourguet P; Bekhechi D; Deugnier YM; Gosselin M Hepatology; 1997 Nov; 26(5):1156-61. PubMed ID: 9362356 [TBL] [Abstract][Full Text] [Related]